A structural comparison of inhibitor binding to PKB, PKA and PKA-PKB chimera.

Although the crystal structure of the anti-cancer target protein kinase B (PKBbeta/Akt-2) has been useful in guiding inhibitor design, the closely related kinase PKA has generally been used as a structural mimic due to its facile crystallization with a range of ligands. The use of PKB-inhibitor crystallography would bring important benefits, including a more rigorous understanding of factors dictating PKA/PKB selectivity, and the opportunity to validate the utility of PKA-based surrogates. We present a "back-soaking" method for obtaining PKBbeta-ligand crystal structures, and provide a structural comparison of inhibitor binding to PKB, PKA, and PKA-PKB chimera. One inhibitor presented here exhibits no PKB/PKA selectivity, and the compound adopts a similar binding mode in all three systems. By contrast, the PKB-selective inhibitor A-443654 adopts a conformation in PKB and PKA-PKB that differs from that with PKA. We provide a structural explanation for this difference, and highlight the ability of PKA-PKB to mimic the true PKB binding mode in this case.

[1]  R. Huber,et al.  Mutants of protein kinase A that mimic the ATP-binding site of protein kinase B (AKT). , 2003, Journal of molecular biology.

[2]  P. Workman,et al.  Corrigendum: Drugging the PI3 kinome , 2006, Nature Biotechnology.

[3]  S. Rosenberg,et al.  implications for cancer therapy , 1996 .

[4]  L. Toledo,et al.  Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors. , 2000, Structure.

[5]  Patrick Gaillard,et al.  Molecular Lipophilicity Potential, a tool in 3D QSAR: Method and applications , 1994, J. Comput. Aided Mol. Des..

[6]  C. Lindsley,et al.  The Akt/PKB family of protein kinases: a review of small molecule inhibitors and progress towards target validation. , 2005, Current topics in medicinal chemistry.

[7]  P. Cohen,et al.  Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα , 1997, Current Biology.

[8]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[9]  Brian A. Hemmings,et al.  Crystal structure of an activated Akt/Protein Kinase B ternary complex with GSK3-peptide and AMP-PNP , 2002, Nature Structural Biology.

[10]  R. Huber,et al.  Design and crystal structures of protein kinase B-selective inhibitors in complex with protein kinase A and mutants. , 2005, Journal of medicinal chemistry.

[11]  V. Stoll,et al.  Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation. , 2006, Bioorganic & medicinal chemistry letters.

[12]  Qun Li,et al.  Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer. , 2002, Current topics in medicinal chemistry.

[13]  Yan Shi,et al.  Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo , 2005, Molecular Cancer Therapeutics.

[14]  Michael Koutsilieris,et al.  The Akt pathway: molecular targets for anti-cancer drug development. , 2004, Current cancer drug targets.

[15]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[16]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[17]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[18]  A. Kral,et al.  Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors , 2022 .

[19]  Stephen K Burley,et al.  A Novel Mode of Gleevec Binding Is Revealed by the Structure of Spleen Tyrosine Kinase* , 2004, Journal of Biological Chemistry.

[20]  B. Hemmings,et al.  Advances in protein kinase B signalling: AKTion on multiple fronts. , 2004, Trends in biochemical sciences.

[21]  Ian Collins,et al.  Structure-based design of isoquinoline-5-sulfonamide inhibitors of protein kinase B. , 2006, Bioorganic & medicinal chemistry.

[22]  Michael J Hartshorn,et al.  AstexViewer: a visualisation aid for structure-based drug design. , 2002, Journal of computer-aided molecular design.

[23]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[24]  B. Hemmings,et al.  Inhibition of protein kinase B/Akt. implications for cancer therapy. , 2002, Pharmacology & therapeutics.

[25]  Marcel L Verdonk,et al.  Automated Protein–Ligand Crystallography for Structure‐Based Drug Design , 2006, ChemMedChem.

[26]  R. Huber,et al.  Crystal Structures of Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Isoquinolinesulfonyl Protein Kinase Inhibitors H7, H8, and H89 , 1996, The Journal of Biological Chemistry.

[27]  M. Vieth,et al.  Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.

[28]  J. Pflugrath,et al.  The finer things in X-ray diffraction data collection. , 1999, Acta crystallographica. Section D, Biological crystallography.

[29]  Andrew D. Barbour,et al.  Stein's Method And Applications , 2005 .

[30]  D W Cushman,et al.  Design of potent competitive inhibitors of angiotensin-converting enzyme. Carboxyalkanoyl and mercaptoalkanoyl amino acids. , 1977, Biochemistry.

[31]  J. Gills,et al.  The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt , 2004, Expert opinion on investigational drugs.

[32]  R. Huber,et al.  Structural and functional analyses of benzamidine-based inhibitors in complex with trypsin: implications for the inhibition of factor Xa, tPA, and urokinase. , 1998, Journal of medicinal chemistry.

[33]  T Honma,et al.  Crystallographic Approach to Identification of Cyclin-dependent Kinase 4 (CDK4)-specific Inhibitors by Using CDK4 Mimic CDK2 Protein* , 2001, The Journal of Biological Chemistry.

[34]  Richard D. Taylor,et al.  Improved protein–ligand docking using GOLD , 2003, Proteins.

[35]  V. Stoll,et al.  Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer. , 2006, Bioorganic & medicinal chemistry letters.

[36]  Tamar Geiger,et al.  Toward a PKB inhibitor: modification of a selective PKA inhibitor by rational design. , 2002, Biochemistry.

[37]  B. Hemmings,et al.  Ten years of protein kinase B signalling: a hard Akt to follow. , 2001, Trends in biochemical sciences.

[38]  Gerhard Klebe,et al.  ZZ made EZ: influence of inhibitor configuration on enzyme selectivity. , 2003, Journal of molecular biology.

[39]  Andrew D. Hamilton,et al.  Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt , 2004, Cancer Research.

[40]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[41]  I. Bossis,et al.  Protein kinase A and its role in human neoplasia: the Carney complex paradigm. , 2004, Endocrine-related cancer.

[42]  D. Barford,et al.  Molecular mechanism for the regulation of protein kinase B/Akt by hydrophobic motif phosphorylation. , 2002, Molecular cell.

[43]  S. Taylor,et al.  Expression of the catalytic subunit of cAMP-dependent protein kinase in Escherichia coli: multiple isozymes reflect different phosphorylation states. , 1993, Protein engineering.

[44]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[45]  I. Bossis,et al.  Minireview: PRKAR1A: normal and abnormal functions. , 2004, Endocrinology.

[46]  P. Workman,et al.  Drugging the PI3 kinome , 2006, Nature Biotechnology.

[47]  F. Allen.  The Cambridge Structural Database: a quarter of a million crystal structures and rising. , 2002, Acta crystallographica. Section B, Structural science.

[48]  Wolfgang Wende,et al.  Plasmodium falciparum glutathione S‐transferase—Structural and mechanistic studies on ligand binding and enzyme inhibition , 2006, Protein science : a publication of the Protein Society.

[49]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[50]  Enrique Casado,et al.  PI3K/Akt signalling pathway and cancer. , 2004, Cancer treatment reviews.

[51]  G. Petsko,et al.  Weakly polar interactions in proteins. , 1988, Advances in protein chemistry.

[52]  R. Huber,et al.  Structure-based optimization of novel azepane derivatives as PKB inhibitors. , 2004, Journal of medicinal chemistry.

[53]  Zhijian Zhao,et al.  Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. , 2005, Bioorganic & medicinal chemistry letters.